The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study

RCT (n=163) reports mean (SD) change in plaque volume in exenatide group (0.3% [2%]) did not differ from placebo (−2.2% [8%]) (p= 0.4); and results raise possibility that short-term anti-atherosclerotic effects may not play a central role in cardiovascular benefits of GLP-1s.

Diabetes Care